Sarepta Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
SRPT$16.42-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive (Loss)Income
(in thousands, except per share data)
| For the Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Revenues: | |||
| Products, net | $1,864,296 | $1,787,960 | $1,144,876 |
| Collaboration and other | 333,941 | 114,019 | 98,460 |
| Total revenues | 2,198,237 | 1,901,979 | 1,243,336 |
| Cost of sales (excluding amortization of in-licensed rights) | 839,605 | 319,099 | 150,343 |
| Research and development | 1,522,066 | 804,522 | 877,387 |
| Selling, general and administrative | 491,716 | 557,872 | 481,871 |
| Restructuring charge | 42,009 | — | — |
| Amortization of in-licensed rights | 2,622 | 2,405 | 1,559 |
| Total cost and expenses | 2,898,018 | 1,683,898 | 1,511,160 |
| Operating (loss) income | (699,781) | 218,081 | (267,824) |
| Other (loss) income, net: | |||
| Other (expense) income, net | (19,306) | 42,693 | 33,055 |
| Gain (loss) on debt extinguishment | 16,862 | — | (387,329) |
| Gain from sale of Priority Review Voucher | — | — | 102,000 |
| Total other (loss) income, net | (2,444) | 42,693 | (252,274) |
| (Loss) income before income tax expense | (702,225) | 260,774 | (520,098) |
| Income tax expense | 11,185 | 25,535 | 15,879 |
| Net (loss) income | $(713,410) | $235,239 | $(535,977) |
| Other comprehensive income (loss): | |||
| Unrealized gains (losses) on investments, net of tax | $490 | $(1,136) | $2,582 |
| Total other comprehensive income (loss) | 490 | (1,136) | 2,582 |
| Comprehensive (loss) income | $(712,920) | $234,103 | $(533,395) |
| (Loss) earnings per share: | |||
| Basic | $(7.13) | $2.47 | $(5.80) |
| Diluted | $(7.13) | $2.34 | $(5.80) |
| Weighted average number of shares of common stock used in computing (loss) earnings per share: | |||
| Basic | 100,120 | 95,075 | 92,398 |
| Diluted | 100,120 | 107,875 | 92,398 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.